07:28 AM EDT, 10/21/2024 (MT Newswires) -- Novo Nordisk ( NVO ) said Monday a study of its Rybelsus oral semaglutide as an adjunct to the standard of care for preventing major adverse cardiovascular events met its primary goal.

The drugmaker said the study showed a statistically significant and superior reduction in major adverse cardiovascular events of 14% for people treated with oral semaglutide compared to placebo.

The study enrolled 9,650 people with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease.

Novo Nordisk ( NVO ) said it expects to file for regulatory approval of a label expansion for Rybelsus in the US and EU around the turn of the year.

Price: 117.18, Change: -0.91, Percent Change: -0.77